Annual CFF
$16.13 M
-$89.03 M-84.66%
December 31, 2023
Summary
- As of March 13, 2025, PSTX annual cash flow from financing activities is $16.13 million, with the most recent change of -$89.03 million (-84.66%) on December 31, 2023.
- During the last 3 years, PSTX annual CFF has fallen by -$297.81 million (-94.86%).
Performance
PSTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
$742.00 K
+$742.00 K+100.00%
September 30, 2024
Summary
- As of March 13, 2025, PSTX quarterly cash flow from financing activities is $742.00 thousand, with the most recent change of +$742.00 thousand (+100.00%) on September 30, 2024.
- Over the past year, PSTX quarterly CFF has stayed the same.
Performance
PSTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
$699.00 K
-$14.20 M-95.31%
September 30, 2024
Summary
- As of March 13, 2025, PSTX TTM cash flow from financing activities is $699.00 thousand, with the most recent change of -$14.20 million (-95.31%) on September 30, 2024.
- Over the past year, PSTX TTM CFF has stayed the same.
Performance
PSTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PSTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -84.7% | 0.0% | 0.0% |
| 3 y3 years | -94.9% | -60.0% | -69.9% |
| 5 y5 years | -70.2% | -90.6% | -99.6% |
PSTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.7% | -84.4% | -99.0% | -105.8% | -99.3% | at low |
| 5 y | 5-year | -94.9% | -84.4% | -99.6% | -105.8% | -99.8% | at low |
| alltime | all time | -94.9% | -84.4% | -99.6% | -105.8% | -99.8% | at low |
Poseida Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $742.00 K(>+9900.0%) | $699.00 K(-95.3%) |
| Jun 2024 | - | $0.00(-100.0%) | $14.90 M(0.0%) |
| Mar 2024 | - | -$43.00 K(<-9900.0%) | $14.90 M(-7.6%) |
| Dec 2023 | $16.13 M(-84.7%) | $0.00(-100.0%) | $16.13 M(-0.4%) |
| Sep 2023 | - | $14.94 M(>+9900.0%) | $16.18 M(-79.0%) |
| Jun 2023 | - | $0.00(-100.0%) | $77.08 M(-0.0%) |
| Mar 2023 | - | $1.19 M(+1944.8%) | $77.11 M(-26.7%) |
| Dec 2022 | $105.16 M(+4076.3%) | $58.00 K(-99.9%) | $105.16 M(-0.2%) |
| Sep 2022 | - | $75.84 M(>+9900.0%) | $105.34 M(+236.0%) |
| Jun 2022 | - | $32.00 K(-99.9%) | $31.35 M(-0.1%) |
| Mar 2022 | - | $29.23 M(>+9900.0%) | $31.39 M(+1146.6%) |
| Dec 2021 | $2.52 M | $236.00 K(-87.3%) | $2.52 M(+8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $1.85 M(+2668.7%) | $2.32 M(-98.9%) |
| Jun 2021 | - | $67.00 K(-81.4%) | $206.99 M(-33.2%) |
| Mar 2021 | - | $360.00 K(+847.4%) | $309.95 M(-1.3%) |
| Dec 2020 | $313.94 M(+91.0%) | $38.00 K(-100.0%) | $313.94 M(+0.0%) |
| Sep 2020 | - | $206.53 M(+100.5%) | $313.92 M(+172.4%) |
| Jun 2020 | - | $103.03 M(+2270.6%) | $115.25 M(+58.3%) |
| Mar 2020 | - | $4.35 M(>+9900.0%) | $72.80 M(-55.7%) |
| Dec 2019 | $164.37 M(+204.0%) | $14.00 K(-99.8%) | $164.37 M(+0.0%) |
| Sep 2019 | - | $7.86 M(-87.0%) | $164.36 M(+5.0%) |
| Jun 2019 | - | $60.58 M(-36.8%) | $156.49 M(+63.2%) |
| Mar 2019 | - | $95.92 M | $95.92 M |
| Dec 2018 | $54.07 M(+162.1%) | - | - |
| Dec 2017 | $20.63 M | - | - |
FAQ
- What is Poseida Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Poseida Therapeutics?
- What is Poseida Therapeutics annual CFF year-on-year change?
- What is Poseida Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly CFF year-on-year change?
- What is Poseida Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Poseida Therapeutics?
- What is Poseida Therapeutics TTM CFF year-on-year change?
What is Poseida Therapeutics annual cash flow from financing activities?
The current annual CFF of PSTX is $16.13 M
What is the all time high annual CFF for Poseida Therapeutics?
Poseida Therapeutics all-time high annual cash flow from financing activities is $313.94 M
What is Poseida Therapeutics annual CFF year-on-year change?
Over the past year, PSTX annual cash flow from financing activities has changed by -$89.03 M (-84.66%)
What is Poseida Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of PSTX is $742.00 K
What is the all time high quarterly CFF for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly cash flow from financing activities is $206.53 M
What is Poseida Therapeutics quarterly CFF year-on-year change?
Over the past year, PSTX quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Poseida Therapeutics TTM cash flow from financing activities?
The current TTM CFF of PSTX is $699.00 K
What is the all time high TTM CFF for Poseida Therapeutics?
Poseida Therapeutics all-time high TTM cash flow from financing activities is $313.94 M
What is Poseida Therapeutics TTM CFF year-on-year change?
Over the past year, PSTX TTM cash flow from financing activities has changed by $0.00 (0.00%)